RxDoctor Payments Data

Adam Sobel, MD

Internal Medicine · Wynnewood, PANPI 1639100043

Payments from drug & device makers

$305in general payments, 2019–2025

Across 17 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$85
  • Daiichi Sankyo Inc.$45
  • GSK$32
  • Lilly USA, LLC$32
  • Bayer$22
  • Novo Nordisk$22
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$305100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$305 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$128,659
Medicare patients
315
Services billed
1,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin132$100,880
EliquisApixaban240$80,035
OzempicSemaglutide77$77,353
BiktarvyBictegrav/Emtricit/Tenofov Ala13$54,442
JanuviaSitagliptin Phosphate85$49,171
XifaxanRifaximin25$39,930
Abilify MaintenaAripiprazole12$36,061
AustedoDeutetrabenazine15$32,961
XareltoRivaroxaban89$26,780
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr34$17,149
FarxigaDapagliflozin Propanediol30$16,612
Breo ElliptaFluticasone/Vilanterol28$13,367
Atorvastatin Calcium529$9,488
CreonLipase/Protease/Amylase19$7,986
EntrestoSacubitril/Valsartan16$6,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$77,35377 claims
GSKAnoro Ellipta, Breo Ellipta$32$30,51662 claims
AstraZenecaFarxiga$17$16,61230 claims
AbbVieCreon$85$7,98619 claims
NovartisEntresto$20$6,67716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →